4-[9-[1,1-dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-9H-xanthen-3-yl]-N,N-dimethylbenzamide | 1337530-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4-[9-[1,1-dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-9H-xanthen-3-yl]-N,N-dimethylbenzamide
• 英文别名: N,N-dimethyl-4-[9-[2-methyl-1-oxo-1-(1,3,4-thiadiazol-2-ylamino)propan-2-yl]-9H-xanthen-3-yl]benzamide
• CAS: 1337530-81-0
• 化学式: C₂₈H₂₆N₄O₃S
• 分子量: 498.605
• InChiKey: ORVRISQWQZXOFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(3-hydroxy-9H-xanthen-9-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide 在 potassium phosphate 、 四(三苯基膦)钯 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 4-[9-[1,1-dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-9H-xanthen-3-yl]-N,N-dimethylbenzamide
  参考文献：
  名称：

  Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826)

  摘要：

  Structurally novel 5H-chromeno[2,3-b]pyridine (azaxanthene) selective glucocorticoid receptor (GR) modulators have been identified. A screening paradigm utilizing cellular assays of GR-mediated transrepression of proinflammatory transcription factors and transactivation of GR-dependent genes combined with three physiologically relevant assays of cytokine induction in human whole blood has allowed for the identification of high affinity, selective GR ligands that display a broad range of pharmacological profiles. Agonist efficacy in reporter assays can be tuned by halogenation of a pendent phenyl ring and correlates well with efficacy for cytokine inhibition in human whole blood. A hypothetical binding mode is proposed, invoking an expanded ligand binding pocket resembling that of arylpyrazole-bound GR structures. Two compounds of dose structural similarity (35 and 37; BMS-776532 and BMS-791826, respectively) have been found to maintain distinct and consistent levels of partial agonist efficacy across several assays, displaying anti-inflammatory activity comparable to that of prednisolone 2 in suppressing cytokine production in whole blood and in rodent models of acute and chronic inflammation.

  DOI：

  10.1021/jm200879j

文献信息

• Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (<i>S</i>)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5<i>H</i>-chromeno[2,3-<i>b</i>]pyridin-2-yl)-2-fluoro-<i>N</i>,<i>N</i>-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826)
  作者：David S. Weinstein、Hua Gong、Arthur M. Doweyko、Mark Cunningham、Sium Habte、Jin Hong Wang、Deborah A. Holloway、Christine Burke、Ling Gao、Victor Guarino、Julie Carman、John E. Somerville、David Shuster、Luisa Salter-Cid、John H. Dodd、Steven G. Nadler、Joel C. Barrish

  DOI：10.1021/jm200879j

  日期：2011.10.27

  Structurally novel 5H-chromeno[2,3-b]pyridine (azaxanthene) selective glucocorticoid receptor (GR) modulators have been identified. A screening paradigm utilizing cellular assays of GR-mediated transrepression of proinflammatory transcription factors and transactivation of GR-dependent genes combined with three physiologically relevant assays of cytokine induction in human whole blood has allowed for the identification of high affinity, selective GR ligands that display a broad range of pharmacological profiles. Agonist efficacy in reporter assays can be tuned by halogenation of a pendent phenyl ring and correlates well with efficacy for cytokine inhibition in human whole blood. A hypothetical binding mode is proposed, invoking an expanded ligand binding pocket resembling that of arylpyrazole-bound GR structures. Two compounds of dose structural similarity (35 and 37; BMS-776532 and BMS-791826, respectively) have been found to maintain distinct and consistent levels of partial agonist efficacy across several assays, displaying anti-inflammatory activity comparable to that of prednisolone 2 in suppressing cytokine production in whole blood and in rodent models of acute and chronic inflammation.